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DOI 10.1016/j.ccr.2012.02.019SUMMARYThe von Hippel-Lindau tumor-suppressor gene (VHL) is lost in most clear cell renal cell carcinomas (ccRCC).
Here, using human ccRCC specimens, VHL-deficient cells, and xenograft models, we show that miR-204 is
a VHL-regulated tumor suppressor acting by inhibiting macroautophagy, with MAP1LC3B (LC3B) as a direct
and functional target. Of note, higher tumor grade of human ccRCC was correlated with a concomitant
decrease in miR-204 and increase in LC3B levels, indicating that LC3B-mediated macroautophagy is neces-
sary for RCC progression. VHL, in addition to inducing endogenous miR-204, triggered the expression of
LC3C, an HIF-regulated LC3B paralog, that suppressed tumor growth. These data reveal a function of VHL
as a tumor-suppressing regulator of autophagic programs.INTRODUCTION
Clear cell renal cell carcinoma (ccRCC), the most frequent and
malignant type of renal cancer, is characterized by early loss of
the von Hippel-Lindau tumor-suppressor gene (VHL) in a majority
(60%–80%) of tumors. One well-recognized oncogenic effect of
VHL loss is induction of the hypoxia inducible factor (HIF) and
HIF-regulated genes, which stimulate angiogenesis and thus
providenutrientsnecessary for tumorgrowth (GossageandEisen,
2010). Discovery of this pathway laid the groundwork for the
development of several antiangiogenic therapeutic approaches
for treatment of ccRCC (Heng and Bukowski, 2008). However,
antiangiogenic therapies have not lived up to their initial promise,
which suggests that tumor growth and survival might be sup-
ported by alternative sources of nutrients such as autophagy.Significance
ccRCC tumor growth depends on abundant angiogenesis and
VHL loss and induction of hypoxia-inducible factor (HIF) and HI
HIF-independent manner, access to nutrients from intracellula
This autophagic program is necessary for tumor growth. In
LC3C, which exercises tumor-suppressing activity. These fin
control of different autophagic programs. Addiction of cance
miR-204 could be used in ccRCC therapy with minimal effects
532 Cancer Cell 21, 532–546, April 17, 2012 ª2012 Elsevier Inc.Autophagy is a complex and tightly regulated homeostatic
process that allows a cell to eliminate defective organelles and
molecules and to recycle nutrients for survival under deprived
conditions. Dependence of cancer cells on such oncogenic au-
tophagy has been demonstrated (Degenhardt et al., 2006; Jin
et al., 2007). Conversely, changes in the rate of autophagy may
result in metabolic imbalance and cell death (Mathew et al.,
2007; White and DiPaola, 2009). Classic macroautophagy
involves a process utilizing ubiquitin-like cascades of ATG
proteins leading to the formation of double-membrane autopha-
gosomes containing cytoplasm, ribosomes, and other organ-
elles. Autophagosomes ultimately fuse with lysosomes targeting
the cargo for proteolytic degradation (He and Klionsky, 2009).
The initial step includes formation of an isolation membrane
(phagophore), which can originate from the endoplasmicactivation of glycolytic metabolic pathways that result from
F targets. Here we show that loss of VHL also promotes, in an
r sources through activation of LC3B-mediated autophagy.
addition, VHL, by repressing HIF, induces expression of
dings support a role for VHL as a tumor suppressor in the
r cells to oncogenic autophagy creates the possibility that
on normal renal cells.
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Regulation of Autophagy by VHLreticulum (Axe et al., 2008), outer mitochondrial membrane (Hai-
ley et al., 2010), or plasma membrane (Ravikumar et al., 2010).
The diverse origins of membranes for autophagic vacuoles
create the possibility for adaptive and alternative autophagic
programs that can be activated during different types or dura-
tions of starvation in a cell-type-specific manner. Phagophores
interact with several regulatory multiprotein complexes,
including mTOR and AMPK-regulated ULK complexes and the
Beclin 1/class III PI3K complex. Further processing of the
phagophore to the mature autophagosome requires covalent
conjugation of ATG12 to ATG5 via a mechanism involving the
E1-like enzyme ATG7 and the E2-like enzyme ATG10. The
ATG12-ATG5 conjugate forms a complex with ATG16L and
carries the final E3-like conjugation of the microtubule-associ-
ated protein light chain (MAP1LC3, here referred to as LC3) on
an exposed C-terminal glycine to phosphatidylethanolamine
(PE) initiated by the ubiquitinylation-like cascade processed by
ATG7(E1) and ATG3 (E2) factors (Tanida et al., 2004). The
appearance of the lipidated form of LC3 (LC3-II) in the autopha-
gosome membrane is a commonly used marker of ongoing
autophagy and can be quantified by endpoint flux analysis in
the presence of lysosomal inhibitors (Rubinsztein et al., 2009;
Klionsky et al., 2008).
In contrast to a single LC3 (ATG8) in yeast, mammalian cells
have six different orthologs of ATG8 (LC3A, LC3B, LC3C,
GABARAP, GABARAPL1, and GATE16/GABARAPL2) (Tanida
et al., 2004). While tissue-specific patterns of expression and
intracellular localization have been reported (Tanida et al.,
2004), the precise functions of the individual orthologs are not
well understood. Specific involvement of the different orthologs
at different stages of autophagosome formation was observed
in HeLa cells, with the LC3 family participating in earlier stages
of autophagosome membrane elongation, and the GABARAP
family involved in later stages of maturation (Weidberg et al.,
2010). At least some functional redundancy among orthologs is
expected based on similarities in sequence and structure (Wu
et al., 2006) and the overlapping partner-protein binding patterns
(Behrends et al., 2010). It is interesting that an alternative ATG5-/
ATG7-/LC3B-independent pathway of autophagy has been
described, wherein autophagosomes are derived from trans-
Golgi and late endosomes in a RAB9-dependent manner
(Nishida et al., 2009). The existence of multiple autophagic
programs suggests differential functions dependent on the
cellular context. Therapeutic manipulations of autophagy may
provide anticancer treatments alternative to or supporting of
antiangiogenic therapies. In that respect, the small-molecule
STF-62247 has been identified as a stimulator of autophagy
leading to cell death and inhibition of RCC growth in xenograft
models (Turcotte et al., 2008). On the other hand, inhibition of au-
tophagy by chloroquine appears to cause robust tumor regres-
sion in the case of pancreatic cancer (Yang et al., 2011). Thus,
autophagy represents a therapeutic target in need of further
investigation.
MicroRNAs (miRs) are small noncoding RNAs that modulate
gene expression (Selbach et al., 2008). There is ample evidence
that miRs have regulatory functions in cancer initiation, progres-
sion, and metastasis (Lu et al., 2005; Calin and Croce, 2006).
Introduction of stabilized miRs may restore lost tumor
suppressor activity (Czech, 2006; Negrini et al., 2007; Tongand Nemunaitis, 2008; Kota et al., 2009). Conversely, the use
of antagomirs may allow for a decrease in the level and activity
of miRs that promote oncogenesis (Kru¨tzfeldt et al., 2005).
MiR-204 is expressed from the large intron 6 of TRPM3, which
is located on chromosome 9q21.12 and encodes a transient
receptor potential, Ca2+-permeable, nonselective cation channel
(Oberwinkler and Phillipp, 2007) (Figure 1A). Both miR-204 and
TRPM3 are expressed at higher levels in human kidney as
compared with other organ tested (Lu et al., 2005).
Here, we investigate the role of VHL and miR-204 in the regu-
lation of autophagic programs in ccRCC.
RESULTS
MiR-204 Acts as a Tumor Suppressor in RCC
We analyzed the expression of miR-204 in 128 human ccRCC
with known VHL status and, in 114 cases, a matched normal
kidney specimen. ThemiR-204 level was significantly decreased
in ccRCC as compared with matched normal kidney tissue in
both paired (Figure 1B) and unpaired (data not shown) analyses.
MiR-211 (Figure S1A available online), is a miR-204 paralog
expressed from intron 6 of TRPM1 on chromosome 15q13.3.
Steady-state levels of miR-211 were also reduced in tumors as
compared to normal kidneys, but the absolute expression levels
of this miR were about 100-fold lower than that of miR-204 (Fig-
ure 1B). In contrast, HIF-inducible miR-210 (Kulshreshtha et al.,
2007) was uniformly induced in ccRCC as compared with normal
kidney, as reported by others (Figure 1B) (Nakada et al., 2008;
Jung et al., 2009; Juan et al., 2010).
MiR-204 inhibited the growth of RCC in two different xenograft
models. In the first model, intratumoral injections of lentivirus
particles containing wild-type pre-miR-204 arrested subcuta-
neous tumor growth, as compared with tumors injected with
the same titer (107) of miR-204 carrying a 3-nucleotide mutation
of its seed sequence (Figures 1C and S1A), which does not
have miR-204 activity (see Figure 3Bb). The levels of wild-type
miR-204 were in the range of miR-204 levels in normal kidneys
(Figure S1B). Inhibition of tumor growth was accompanied by
areas of focal necrosis, which stained positively for the necrosis
marker C9, in the tumor regions directly exposed to injections
(Figure 1D). Such necrosis was not observed in tumors injected
with mutated miR-204 (Figure 1D). In an independent series of
experiments, 786-O VHL() cells were transduced with lentiviral
particles containing wild-type or mutated pre-miR-204 and then
injected under the kidney capsules of nude mice. In each case,
initial transduction efficiency was determined to be above 95%
based on the number of cells expressing green fluorescent
protein (Figure S1C), and the expression levels of miR-204
were also in the range of that measured in normal kidneys
(Figure S1B). While the effect of miR-204 expression on tumor
incidence was relatively small, there was a large decrease in
the growth of tumors upon expression of miR-204 (Figure 1Ea).
Moreover, tumors formed by 786-O cells expressing miR-204
were confined to the injection site under the capsule, with no
infiltration of the kidney parenchyma (Figures 1Eb and 1Ec). In
contrast, cells transduced with inactive mutant miR-204 formed
highly invasive tumors that extensively infiltrated the kidney (Fig-
ure 1Ed). Taken together, these results indicate that miR-204
has tumor-suppressing activity.Cancer Cell 21, 532–546, April 17, 2012 ª2012 Elsevier Inc. 533
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Figure 1. MiR-204 Has Tumor-Suppressing Activity in Renal Clear Cell Carcinoma
(A) Localization of miR-204 at the 50 end of intron 6 of the host gene, TRPM3.
(B) Expression of miR-204, its paralogmiR-211, andmiR-210 in human ccRCC as compared with normal kidney tissue. Quantification of the indicated normalized
miR levels (log2) of the total unpaired kidney (K; n = 114) and tumor (T; n = 128) samples are shown. The boxes represent lower and upper quartiles separated by
the median (thick horizontal line), and the whiskers extend up to the minimum and maximum values, excluding points that are outside the 1.5 interquartile range
from the box (marked as circles). Means ± SD of each distribution are indicated by closed dots and crosses on the whiskers, respectively. All differences were
statistically significant at p < 0.001.
(C) Growth of preformed 786-O VHL() tumors in subcutaneous xenografts injected every other day over a period of 9 days with lentiviral particles of wild-type
pre-miR-204 (WT) or pre-miR-204 with the 3 bp mutation (mut). The data are cumulative over two independent series of injections. Representative samples from
each group of tumors are shown. Scale bar, 1 cm.
(D) Representative images of H&E-stained or C9 antibody-probed sections from tumors injected with wild-type (top) or mutant (bottom) pre-miR-204. A section
from a noninjected tumor stained for C9 is shown as a control. Scale bars, 200 mm.
(E) (a) Incidence and size of RCC tumors resulting from transduced cells injected under the kidney capsules of nude mice. (b and c) Examples of H&E-stained
sections of tumors formed by cells transduced with wild-type pre-miR-204 or (d) with mutant pre-miR-204. Scale bar, 200 mm.
See also Figure S1.
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Consistent with the ccRCC tumor data, miR-204 levels in
VHL() 786-O and A498 RCC cells were very low. Expression
of miR-204, but not miR-211, was induced by reconstitution of
wild-type VHL in 786-O and A498 cells, while expression of
miR-210 was repressed under the same conditions, as expected
(Figure 2A). Conversely, VHL knockdown in the VHL-positive
Caki-1 cell line led to decreased expression of miR-204 (Fig-
ure 2B). Moreover, there was a positive and significant correla-
tion between normalized miR-204 levels and VHL protein levels
in normal human kidneys (Figures 2C and 2D). We also found
that VHL-induced expression ofmiR-204 correlated with expres-534 Cancer Cell 21, 532–546, April 17, 2012 ª2012 Elsevier Inc.sion of two short transcripts from TRPM3, TRPM3-005 and -010,
but not with expression of the large transcript encoding the full-
length protein (Figures S2A and S2B). A transcriptional module
with a putative promoter was identified upstream from the first
exon of these short transcripts, suggesting that miR-204 is coex-
pressed with transcripts that do not encode the full-length
protein. We have also determined that expression of miR-204
was not regulated by hypoxia lasting from 8 to 48 hr (Figure S2C),
treatment with the prolyl hydroxylase inhibitor DMOG (Fig-
ure S2D), or inhibition of HIF-2a by siRNAs (Figure S2E),
while all these treatments altered expression of HIF-regulated
miR-210 as predicted. These data establish that VHL positively
AC D
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Figure 2. VHL Positively Regulates Expression of MiR-204
(A) Change in the level of miR-204, -211, and -210 in 786-O and A498 cells with reconstituted wild-type VHL as compared with the level of these miRs in VHL()
cells. Reconstitution of human VHL (HA-VHL) is shown in a western blot.
(B) Change in miR-204 in Caki-1 with VHL knockdown as compared with cells transduced with scramble control shRNA. The western blot demonstrates
knockdown of the endogenous VHL.
(C) Western blot of protein extracts from six human kidneys with high (lanes 1–6) and five human kidneys with low (lanes 7–11) levels of endogenous VHL. The
indicated amounts of protein in extracts from 786-O cells with reconstituted VHLwere blotted for comparison. Values for the normalized levels of miR-204 in each
kidney are shown in a graph under the blot.
(D) Regression analysis of normalized miR-204 levels as a function of normalized VHL levels in kidneys (n = 99). Data are log2-transformed. Each dot represents
a sample, and the solid line represents the linear regression fit, with the Pearson correlation coefficient (r) as well as the slope and intercept of the fitted line shown
in the upper left corner of the box.
See also Figure S2.
Cancer Cell
Regulation of Autophagy by VHLregulates expression of miR-204 in a manner most likely coordi-
nate with some of the TRPM3 transcripts but independent of
HIF activity.
MiR-204 Is Cytotoxic to VHL(–) but Not VHL(+) Cells
In our search for the tumor-suppressing mechanism of miR-204,
we found that expression of exogenous miR-204 in VHL() cells
was cytotoxic if cells were cultured in starvation conditions
(Figures 3A and 3B). It is important to note that the same dose
of exogenous miR-204 was not cytotoxic to 786-O or A498
RCC cells reconstituted with wild-type VHL, which show several
features of normal epithelial cells and are characterized by sup-
pressed ability to form tumors in xenograft models, or to HK-2-
immortalized renal epithelial cells (Figure 3Ba). The levels of
exogenous miR-204 measured in VHL() or VHL(+) RCC cells
or HK2 cells a were very similar. The effect required miR-204
targeting activity, as mutation of three nucleotides within the
core binding site of miR-204 abolished this cytotoxic effect (Fig-
ure 3Bb). Figure 3C shows an example of dying VHL() cells with
extensive cytoplasmic vacuolization, in contrast to healthy
VHL(+) cells. The cytotoxic effect of miR-204 was significantlyattenuated when cells were continuously grown in 10% serum
(Figure 3Bb). Similarly, if VHL() RCC cells starved for 48 hr
were treated with fresh medium containing 10% fetal calf serum
for 6 hr before miR-204 was applied, the cytotoxic effect of
miR-204 was greatly diminished (Figure 3D). Moreover, when
cells were treated with 10 mM glucose 16 hr after addition of
miR-204 (before the beginning of massive cell death), cell death
was greatly reduced (Figure 3E), suggesting that cell death
resulted from starvation.
By using different approaches, we excluded a role for cas-
pase-mediated apoptosis (Figures S3A and S3B), necroptosis
(Figure S3C), or cathepsin-mediated cell death as causes of
the cell death (Figure S3D). Moreover, at the cell densities
used in these experiments, all VHL() and VHL(+) cells prolifer-
ated at similar rates and no differences in their cell cycle kinetics
were observed, despite starvation (data not shown).
MiR-204 Inhibits Macroautophagy Downstream
of Autophagosome Initiation
The aforementioned findings prompted us to investigate the role
of miR-204 in the regulation of starvation-induced autophagy.Cancer Cell 21, 532–546, April 17, 2012 ª2012 Elsevier Inc. 535
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Figure 3. Cytotoxic Effects of MiR-204 in VHL(–) RCC Cells Are Eliminated by Reconstituted Wild-Type VHL
(A) Time line of the procedures performed during the course of experiments shown in (B)–(E). In all experiments, cells were plated at a density of 3,000 per well and
the number of live cells treated with the scramble controls was between 10,000 and 20,000 at the time of collection (also see Figure 3C). Treatments were
repeated at least three times in triplicate.
(B) Percentages of live cells determined by trypan blue exclusion 48 hr after administration of (a) short pre-miR-204 at the indicated concentrations as compared
with the same cells treated with scramble control (Scr) at the same concentrations or (b) lentiviral miR-204 particles administered to the indicated cells as
compared with the same cells treated with mutated miR-204 or empty virus (EV) in the presence of 0.1% or 10% serum. In (a), all experiments were performed in
the presence of 0.1% serum.
(C) Example of a TEMmicrophotograph of VHL() cells dying frommiR-204 cytotoxicity (left) and of live VHL(+) cells (right) under the same conditions. Scale bars,
2 mm.
(D) Numbers of live cells when fresh medium containing 10% serum was given 6 hr before administration of miR-204; see also (A).
(E) Numbers of live cells when medium was supplemented with 10 mM glucose after treatment with miR-204 (see panel A).
See also Figure S3.
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autophagy was inhibited with an upstream inhibitor of macroau-
tophagy, 3-methyladenine (Figure S4A). Moreover, similar to the
effects of miR-204, inhibition of autophagy by knockdown of
the upstream regulator, ATG5, resulted in significantly higher
death of VHL() cells as compared to VHL(+) cells (Figure S4B),
supporting the idea that VHL() cells are more dependent on
autophagy and therefore more sensitive to its inhibition.
Using transmission electron microscopy (TEM) to quantify the
number of autophagic vesicles, we found that treatment with
miR-204 significantly reduced the number of autophagic vesi-
cles in VHL() but not in VHL(+) cells, an effect measured in
both the presence and absence of the autophagy inhibitor, chlo-
roquine (Figure 4A). Moreover the vesicles present in VHL()536 Cancer Cell 21, 532–546, April 17, 2012 ª2012 Elsevier Inc.cells treated with miR-204 were smaller and less developed as
compared with those in the untreated cells. This indicates that
miR-204 inhibits the formation of autophagic vesicles.
Next we determined whether miR-204 exerted its effect during
autophagosome initiation or maturation. MiR-204 did not alter
mTORC1 pathway activity (Figure S4C), indicating that the
effects of miR-204 were not mediated by inhibition of this
pathway. Recently, Weidberg et al. (2010) reported that inhibition
of autophagy by knocking down subfamilies of LC3s or
GABARAPs, which function at the level of autophagosome
maturation, resulted in the accumulation of upstream regulators
that participate in forming the initial membranes, such as
ATG12-ATG5 and ATG16L punctate structures. Treatment with
miR-204 alone significantly increased the number of cells
Cancer Cell
Regulation of Autophagy by VHLexpressing both ATG5-ATG12 and ATG16L punctate structures
and induced an increase in the number of ATG16L puncta per
cell in VHL() cells, but not in VHL(+) cells, grown in 0.1% serum
(Figures 4B, 4C, and S4D). Inhibition of autophagy by chloro-
quine alone also resulted in increased numbers of VHL() 786-
O and A498 cells expressing ATG5-ATG12 puncta, with the
effects significantly weaker in VHL(+) cells (Figure 4B). Chloro-
quine alone had a stronger effect in VHL() cells than miR-204
alone, and simultaneous treatment with both agents resulted in
an accumulation of a similar magnitude to that induced by chlo-
roquine alone. In the case of ATG16L puncta, chloroquine and
miR-204 had similar effects on the number of cells with these
puncta, particularly in 786-O cells (Figures 4C and S4D). Taken
together, these data suggest thatmiR-204 exerts its effect down-
streamof the formationof the initial phagophoremembranesand,
possibly, at the level of autophagosome maturation.
The presence of the lipidated form of LC3 (LC3-II) in the auto-
phagosome membrane is a marker of effective autophagy; we
therefore measured accumulation of the lipidated forms of the
LC3s and GABARAPs. The accumulation of LC3B-II was in-
hibited in VHL() cells by miR-204 in the absence of chloroquine
(Figure 5A, lanes 6 and 5 in each panel). Treatment with chloro-
quine, as expected, induced accumulation of LC3B-II (Figure 5A;
cf. lanes 7 and 5), but miR-204 inhibited this accumulation by
two- to threefold as well (Figure 5A; cf. lanes 7 and 8). In contrast,
while LC3B-II accumulated in response to chloroquine in VHL(+)
cells, this response was not affected by miR-204 (Figure 5A,
lanes 1–4). Similarly, while increased accumulation of LC3B-II
was observed in HK-2 cells in response to chloroquine, levels
of LC3B-II were not affected bymiR-204 (Figure S5A). Treatment
with miR-204 had no effect on the expression of LC3B mRNA in
either cell line (Figure S5B). The accumulation of LC3A-II was not
affected by VHL or miR-204 in any consistent manner. Surpris-
ingly, LC3C-II was expressed only in VHL(+) RCC cells. Among
theGABARAP-like proteins, only GABARAPL2-II showed slightly
decreased expression in response to miR-204 (Figure 5A), and
the dependence of its overall expression on VHL varied depend-
ing on the cell line. GABARP-II was predominantly expressed in
786-O VHL(+) cells and barely detectable in A498 cells. We were
unable to detect expression of GABARAPL1 protein. Immunoflu-
orescence staining confirmed the effects of miR-204 on the
endogenous LC3B in VHL() and VHL(+) RCC cells (Figure S5C),
and the results were consistent with the accumulation of LC3B-II
asmeasured bywestern blot (Figure 5A). Overall, these data indi-
cate that miR-204 inhibits starvation-induced macroautophagy
in VHL(), but not VHL(+) RCC cells, at the stages of autophago-
some maturation and not at initiation.
Knockdown of LC3B resulted in a significantly higher rate of
cell death in VHL() cells as compared with VHL(+) cells in both
786-O and A498 cells (Figures 5B and S5D). This result further
supports the concept of a specific dependence of VHL() cells
on an ATG5/LC3B/miR-204–regulated autophagic program.
LC3B Is a Direct Target of MiR-204 and It Is Necessary
for MiR-204 Cytotoxic Activity
To identify specific miR-204 targets with potential relevance in
the regulation of autophagy, we used several miR target-predic-
tion algorithms (Pictar, TargetScan, Miranda, and Sanger) and
found conserved miR-204 sites in the 30UTRs of two directregulators of autophagy, LC3B and LC3B2. Because LC3B2
is not expressed in 786-O cells, we concentrated our further
analysis on LC3B.
The miR-204 binding site in LC3B mRNA is a broadly
conserved element located between 55 and 61 base pairs (bp)
of the LC3B 30UTR (Figure 6Aa). The 30UTR of LC3B with the
wild-type, but not with a mutant, miR-204–binding site conferred
repression by miR-204 to a luciferase reporter (Figure 6Ab).
Furthermore, as expected, inhibition of miR-204 activity by using
miRZip anti-204 (Mavrakis et al., 2010; Veronese et al., 2010;
Love´n et al., 2010) or siRNA (80%–90% knockdown) upregu-
lated LC3B protein expression in VHL(+) RCC cells (Figure 6B),
indicating that LC3B is under constitutive repression by endog-
enous miR-204. This observation was further supported by a
significant negative correlation between levels of miR-204 and
LC3B protein in the subpopulation of human ccRCC tumors
with the wild-type VHL (Figures 6C and 6D). It is important to
note that the increased accumulation of LC3B-II in the presence
of chloroquine in VHL(+) 786-O cells with miR-204 knocked
down, as comparedwith control VHL(+) cells, indicates an induc-
tion of macroautophagy (Figure 6E, lanes 3 and 4). Moreover,
levels of endogenous LC3B were higher in VHL() as compared
with VHL(+) RCC cells (Figure 5A), consistent with higher levels of
endogenous miR-204 in VHL(+) cells.
It is most important to note that reexpression of LC3B lacking
the 30UTR, and therefore insensitive to miR-204, protected
VHL() 786-O cells from miR-204 cytotoxicity (Figure 6F). Cells
from the same transfection that had lost LC3B-RFP (RFP-nega-
tive cells) or cells transfected with red fluorescent protein (RFP)
alone demonstrated significant miR-204–induced cytotoxicity
(Figure 6F). This rescue from cell death by expression of RFP-
LC3B was accompanied by a reduction in the accumulation of
ATG16L-positive puncta in response to miR-204 in RFP-LC3B–
transfected cells (Figures 6G, S6A, and S6B) as compared to
the effect of miR-204 on nontransfected cells (RFP-negative
cells) or cells transfected with RFP alone (Figures 6G, S6C,
and S6D).
Next, we asked if miR-204 was cytotoxic to cells with LC3B
knocked down. In the first approach, we used 786-O and A498
pools of cells with LC3B stably knocked down (Figure S6E).
Because all cells with stable LC3B knockdown grew very slowly
and progressively died in medium containing 0.1% serum, they
were initially seeded in higher numbers to assure a similar degree
of confluence for cells in the control and LC3B knockdown pools
at the time of treatment with miR-204. Under these conditions,
miR-204 did not have a cytotoxic effect on 786-O or A498 cells
with LC3B knockdown but remained cytotoxic to the control
cells (Figure 6H). We also performed another experiment where
VHL() cells were plated at the same densities, starved as in Fig-
ure 3A, and then transiently transfected with miR-204, siRNA for
LC3B, or both, along with the respective negative controls (Fig-
ure S6F). The effects of miR-204 and LC3B siRNA on cell death
were similar, and there was no additional effect when miR-204
and LC3B siRNA were applied together (Figure S6F).
LC3C Protects VHL(+) RCC Cells from Loss
of LC3B-Mediated Autophagy
The presence of VHL protected RCC cells from the cytotoxic
effects of miR-204 and LC3B knockdown. We found that VHLCancer Cell 21, 532–546, April 17, 2012 ª2012 Elsevier Inc. 537
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Figure 4. MiR-204 Inhibits Macroautophagy in VHL(–) Cells but Not VHL(+) Cells
(A) TEM microphotographs with quantification of the number of autophagic vesicles (AV) (top) and the cytoplasmic area (bottom) in 20 cells under the indicated
conditions in 786-O VHL() and VHL(+) cells. Controls were treated with the same empty lentiviral constructs (EV). The arrows indicate AV. Scale bars, 1 mm.
(B) Representative image of immunofluorescence staining for the endogenous ATG5-ATG12 complex in the indicated conditions in VHL() 786-O cells (a). (b)
Quantification of the percent of cells with puncta versus total number of cells in five independent fields containing on average 50 to 150 cells per field in each
condition in 786-O and A498 cells. Controls were transfected with scramble construct. Scale bar, 50 mm.
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Regulation of Autophagy by VHLis a strong inducer of a largely uncharacterized LC3B paralog,
LC3C (Figures 5A, 7A, and S7A). Reconstitution of VHL in RCC
cells induced (Figures 5A and 7A), while knockdown of VHL in
Caki-1 cells (Figure S7A) reduced, expression of LC3C-II. This
regulation occurred at the level of mRNA (Figure 7B) and was
responsive to HIF-2a. Knockdown of HIF-2a induced LC3C
mRNA (Figure 7C), while activation of HIF-2a using DMOG
repressed LC3C mRNA (Figure 7D). The high levels of LC3C in
VHL(+) cells suggested that LC3C may protect VHL(+) cells
from inhibition of LC3B-mediated autophagy. Testing this possi-
bility, we found that the effect of a single LC3C knockdown (Fig-
ure S7B) on the survival of VHL(+) cells during serum starvation
was comparable to that caused by a single knockdown of
LC3B, and this effect was relatively minor. In contrast, double
LC3B/LC3C knockdown (Figure S7B) reduced the viability of
VHL(+) cells to the levels measured in VHL() cells (Figure 7E).
LC3B-Dependent Autophagy Is Necessary for RCC
Tumor Growth
We then tested the hypothesis that LC3B-mediated autophagy is
necessary for tumor growth. Injection of preformed subcuta-
neous tumors with lentiviral particles containing shRNAs against
LC3B or ATG5 every other day for 9 days resulted in significant
inhibition of tumor growth, as compared with tumors injected
with scrambled shRNA (Figure 8A). A similar result was obtained
when cell lines with stable expression of shRNA targeting LC3B
or ATG5 were injected into the kidneys of nudemice, and growth
of orthotopic tumors was determined after 10 weeks. 786-O
VHL() cells formed tumors in 83% of mice, which was a repro-
ducible incidence in at least five independent experimental
series performed in our laboratory over the past 2 years (see
also Yi et al., 2010). In contrast, injection of cells with knockdown
of LC3B or ATG5 resulted in reduced tumor growth (Figure 8B).
Similar results were obtained using A498 cells, where the forma-
tion of tumors was completely inhibited by the knockdown of
either LC3B or ATG5 (Figure 8C). These data indicate that
ATG5/LC3B-mediated macroautophagy is necessary for the
growth of VHL() RCC tumors in nude mice.
Next, we determined the status of LC3B and ATG5 in 102
human kidney-ccRCC tumor pairs by using quantitative immu-
noblotting with a set of reference standards to normalize results
from multiple blots (Yi et al., 2010). We found a significant corre-
lation between tumor-kidney ratios of the normalized protein
levels for LC3B (all three forms) and ATG5 (Figure S8A). It is
important to note that we found that LC3B levels positively corre-
lated with tumor grade, while miR-204 levels showed a negative
correlation (Figure 8D), suggesting that loss of miR-204 and acti-
vation of autophagy are critical regulators of cancer progression
in sporadic human ccRCC.
Finally, we tested the role of LC3C in the tumor-suppressing
activity of VHL. Knockdown of LC3C in VHL(+) 786-O and
A498 cells (Figure S7B) increased the incidence of small tumor(C) Representative image of immunofluorescence staining for endogenous ATG
Percentage of cells expressing puncta under the indicated conditionswas calcula
the exception of nontreated controls where the number of cells with puncta wa
scramble construct. Scale bars are as indicated in the figure. All measurements s
after treatment with miR-204. This was approximately 24 hr before cell death wa
See also Figure S4.formation by both cell lines when injected into the kidneys of
nude mice (Figure 8E). Moreover, analysis of the human ccRCC
kidney-tumor pairs revealed decrease in LC3C protein expres-
sion in majority of tumors (Figure S8B). These results support
the role of LC3C as a regulator of an autophagic program
involved in tumor suppression.
DISCUSSION
A large majority of human ccRCC is characterized by early loss
of VHL. Here, we identify two pathways that are regulated by
VHL and contribute significantly, although in opposite directions,
to ccRCC tumor growth (Figure 8F). The data clearly demon-
strate that formation of RCC tumors by VHL() RCC cells in
nude mice requires active LC3B/ATG5-dependent autophagy.
Consistent with this, progression of human ccRCC is associated
with increasing levels of LC3B protein. We propose that the
crucial event leading to activation of this protumorigenic auto-
phagic program is the loss of miR-204 and derepression of
LC3B, which in turn, stimulates and/or maintains autophagy. It
is also likely that miR-204 regulates a network of targets that
influence macroautophagy through mechanisms and pathways
converging at the level of LC3B and maturation of the autopha-
gosome without affecting phagophore initiation. This renders
cancer cells addicted to macroautophagic activity, and, thus,
subject to synthetic lethality when macroautophagy is inhibited
by exogenous miR-204, with necrotic cell death caused by
starvation.
We have also discovered that VHL, through inhibition of HIF,
induces LC3C. LC3C, thus far uncharacterized, contributes to
basic autophagic activity in VHL(+) cells at a level similar to
LC3B, but it also mediates an antitumorigenic autophagic
activity as its knockdown increased the incidence of small
tumors in VHL(+) cells. At present, the biochemical activity of
such a program is not understood, but there is growing evidence
for autophagic programs that are not mediated by ATG5/LC3B
(Nishida et al., 2009) or ULK1/2 (Cheong et al., 2011). Thus,
LC3C could be a part of such yet unidentified pathway or could
participate in a nonautophagic tumor-suppressing pathway.
Moreover, an LC3C-specific autophagic program could have
selectivity toward specific pro-oncogenic targets. It is interesting
that the potential functional differences between LC3C and
LC3B/LC3A could be related to the fact that LC3C contains an
unstructured C terminus domain that is not present in other
family members. The mechanism by which HIF represses
expression of LC3C remains to be investigated, but the LC3C
proximal promoter contains E2-boxes, similar to those that
mediate HIF-dependent inhibition of E-cadherin mRNA by
ZFHX1B and SNAI1 (Esteban et al., 2006; Evans et al., 2007).
The requirement for macroautophagy in RCC cells, and the
protective activity of LC3C in normal cells, creates a unique
opportunity for the use of miR-204 or miR-204-like approaches16L puncta in 786-O VHL() and VHL(+) cells under the indicated conditions.
ted as in (B). 100 cells expressing puncta were analyzed for each condition, with
s small and only 30 to 50 cells were counted. Control cells were treated with
hown in this figure were performed on cells grown in 0.1% serum and 24–30 hr
s observed as shown in Figure 3B.
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AB
Figure 5. MiR-204 Specifically Represses Accumulation of LC3B-II in the Flux Experiment
(A) Western blot analysis of LC3 paralogs in extracts from 786-O and A498 cells grown in 0.1% serum conditions. The experiment follows the same treatment
sequence as shown in Figure 3A, with 100 mMchloroquine applied 24 hr after treatment with short pre-miR-204 or scramble control. The cells were collected after
1.5 hr in the case of 786-O cells and after 3 hr in the case of A498 cells, when saturating effects of chloroquine were observed based on the time course
experiments. This was approximately 24 hr before cell death was observed as shown in Figure 3B. Quantification of three independent experiments is shown at
the bottom.
(B) Percentage of live cells measured using trypan blue analysis in 786-O and A498 VHL(+) and VHL() cells transfected with LC3B siRNAs, where 100%
corresponds to live cells counted after transfection with scramble control construct.
Time line is as shown in Figure S4A.
See also Figure S5.
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Regulation of Autophagy by VHLin the treatment of RCC. Such strategies would spare normal
epithelial cells while killing malignant tumor cells. In particular,
a therapeutic approach inducing cytotoxic, rather than cyto-
static, effects is desirable, as the currently used antiangiogenic
treatments are only cytostatic. Of note, treatments for pancreatic
cancer involving general inhibitors of autophagy, such as chloro-
quine, are currently in clinical trials (Yang et al., 2011).540 Cancer Cell 21, 532–546, April 17, 2012 ª2012 Elsevier Inc.While VHL is a positive regulator of miR-204 expression in
normal tissues, it is likely that factors additional to the loss of
VHL could trigger decreased miR-204 expression, particularly
during cancer progression. In that respect, miR-204 is ex-
pressed from locus 9q21.12, and published data indicate that
chromosome 9 is the second most frequently lost chromosome,
after 3p, in ccRCC (20%–30% of tumors) and decreased
Cancer Cell
Regulation of Autophagy by VHLexpression of genes from this region was reported (Fukunaga
et al., 2002; Yoshimoto et al., 2007; Toma et al., 2008). Our initial
evidence points toward coordinated expression of miR-204 with
short, but not full-size, TRPM3 transcripts, which could repre-
sent a more general mechanism for expression of intronic miRs
from long genes.
Taken together, our findings indicate that VHL regulates at
least two autophagic programs through an HIF-independent
pathway activating miR-204 and an HIF-regulated pathway
activating LC3C.
EXPERIMENTAL PROCEDURES
Human RCC Tumors
Fresh-frozen samples of renal clear cell carcinomas (n = 128) and matched
normal kidneys (n = 114) were obtained and analyzed for VHL gene sequence
and protein expression as described earlier (Yi et al., 2010). Specimens were
also analyzed for expression of miR-204, miR-211, and miR-210. All human
samples were anonymous and exempted from institutional review board
protocol.
Cell Culture Methods and Treatments
Pools of human VHL() and VHL(+) 786-O and Caki-1 cells were described by
us before (Mikhaylova et al., 2008; Yi et al., 2010); A498 cells were obtained
from Dr. W. G. Kaelin Jr., (Dana-Farber Institute, Harvard Medical School).
HK-2 cells were purchased from ATCC. All cells were authenticated (Genetica,
Cincinnati, OH). For miR-204 treatments, cells were plated in 12-well cell
culture dishes at 3,000 per well in normal medium. Twenty-four hours later,
the medium was replaced with fresh medium containing 10% or 0.1% serum.
After the next 48 hr, cells were transduced with lentiviral particles containing
wild-type or mutated pri-miR-204 or transfected with the respective short
pre-miR-204, in each case with the appropriate negative controls. Cell viability
was determined 48 hr after miR-204 treatment by trypan blue exclusion. For
the LC3-II flux experiments, cells were plated and treated as described earlier,
and 24 hr after miR-204 treatment, cells were treated with 100 mM chloroquine
to inhibit lysosomal function. Cells were collected at the indicated times and
analyzed by PAGE for the proteins of interest.
Quantitative Real-Time PCR
Total RNA was extracted using the mirVana miRNA Isolation kit (Ambion). For
microRNA analysis, the samples were first reverse transcribed using the
TaqMan microRNA Reverse Transcription kit and miR-specific primers and
probes (TaqMan microRNA Assays, Applied Biosystems) and were quantified
with real-time PCR on an Applied Biosystems 7900HT Fast Real-Time PCR
System. The small nucleolar RNA (snoRNA) RNU44 was used as the internal
control for the DCt calculation. Data are presented normalized to snoRNU44
or as ratios of the normalized values between paired cell lines differing in the
status of VHL or tumor/kidney pairs. For mRNA, qRT-PCR was performed
as described before (Yi et al., 2010), and the sequence of primers is provided
in the Supplemental Experimental Procedures.
Constructs and Plasmids
The following miR-204 reagents were used: Pre-miR-204 precursor and
Pre-miR negative control were purchased from Ambion (Pre-miR-204 miRNA
Precursor Molecules and negative control Pre-miR miRNA Precursor Mole-
cules). Anti-miR-204 and the corresponding negative control were purchased
from Dharmacon (miRIDIAN Hairpin Inhibitor: human hsa-miR-204, and miRI-
DIAN microRNA Hairpin Inhibitor Negative Control #1). HIV-based lenti-miR
pri-micro RNA-204 construct and control lentivector were from System
Biosciences (microRNA Expression Construct Lenti-miR-204 MI0000284
and corresponding lentivector negative control). To alter the miR-204 core
sequence, we performed site-directed mutagenesis on PMIRH204 to replace
the core CCC sequence with a GGG sequence (GenScript). The mutation was
verified by sequencing. A list of siRNA and shRNA constructs is provided in the
Supplemental Experimental Procedures. All lentiviral DNA constructs were
VSV-G envelope packaged (Cincinnati Children’s Hospital Medical CenterViral Vector Core) and infected into cells followed by plasmid-appropriate
selection. The LC3B-RFP construct contained human LC3B-myc fused to
RFP from pDsRed1-N1 in the PRK5 vector and was a gift from Drs. P. Dennis
and C. Mercer (University of Cincinnati). The Luciferase-LC3B-30UTR
construct was based on pLightSwitch_30UTR vector and purchased from
Switchgear Genomics.
Transfections and Transduction Experiments
Transient transfections of microRNA constructs or pools of siRNAs were per-
formed using Lipofectamine 2000 according to the manufacturer’s protocol.
Transductions with lentiviral particles were performed using 2 mg/ml of
polybrene.
Western Blot Analysis
Total cellular lysates were obtained by lysing cells in RIPA buffer containing
proteinase and phosphatase inhibitors. A total of 5 to 30 mg of extracts were
separated on 12% polyacrylamide gels and transferred on to polyvinylidene
fluoride membrane. Blots were probed with relevant antibodies described in
the Supplemental Experimental Procedures. Quantitative immunoblotting for
human RCC tumors and matched kidneys was performed as described in
(Yi et al., 2010).
Mouse Xenograft Experiments
All experiments on mice were performed in accordance with University of
Cincinnati Institutional Animal Care and Use Committee-approved protocol.
For the intrakidney injections, 30,000 cells were resuspended in Matrigel to
a final volume of 30 ml and then slowly injected into the parenchyma of the
kidneys of 4- to 5-week-old athymic nude mice, and tumors were collected
after 10–12weeks. For the subcutaneous injections, 13 106 cells in cell culture
medium were injected subcutaneously into the flanks of the same strain of
nude mice. After 6 weeks, these tumors reached an approximate average
volume of 50 mm3, and mice were randomly assigned to groups in which
the tumors would be injected with specific viral particles containing constructs
encoding mutant miR-204, wild-type miR-204, or specific shRNAs. For each
control and experimental condition, the same titer of viral particles was
used. Injections were performed with 25 ml of supernatant every other day
for a period of 9 days. Before injections, three standard dimensions of the
tumor were measured with a protractor, and the volume of the tumor was
calculated using the equation d1 3 d2 3 d3 3 p/6. At the end of the experi-
ments, mice were sacrificed and tumors were fixed in 4% paraformaldehyde,
paraffin embedded, and hematoxylin and eosin (H&E) stained or processed for
immunocytochemistry using a monoclonal antibody against Complement
Component 9 (Vector Laboratories).
Immunofluorescence Staining
Cells were plated on coverslips and treated with miR-204. At the end of the
experiment, cells were fixed in 4% paraformaldehyde, permeabilized in
0.3% Triton, blocked in 0.1% Triton with 3% bovine serum albumin, and
incubated with primary antibody for 1 hr at 37C. Cells were then washed
and incubated with the Alexa 488-labeled secondary antibody for 1 hr at
room temperature. Confocal images were acquired on a Zeiss LSM510
confocal or by using a Zeiss Axioplan 2 microscope with the appropriate filter
cubes and a Zeiss Axiocam MRm to record the images. The number of cells
expressing puncta and the number of puncta per cell were counted manually.
Preparation of Samples and TEM
Samples were processed in the Electron Microscopy Core at Cincinnati
Children’s Hospital Medical Center. Briefly, cells were washed with PBS and
resuspended in 0.2 M cacodylate buffer with 3% glutaraldehyde. Cells were
postfixed with 1% osmium tetroxide (Electron Microscopy Sciences, Fort
Washington, PA) with 0.2 M sodium cacodylate buffer for 1 hr at 4C. After
three washes with 0.2 M sodium cacodylate buffer, cells were resuspended
in 1% agarose (type IX, Sigma), centrifuged for 5 min at 3,000 rpm, and left
for 24 hr at 4C. The following day, samples were dehydrated and embedded
in LX-112 embedding medium (Ladd Research Industries, Burlington, VT).
Samples were then polymerized for 48 hr at 60C, cut into 100-nm-thick
sections on a USA Reichert-Jung UltraCut E microtome, positioned on 200
mesh grids, and stained with uranyl acetate and lead citrate. TEM wasCancer Cell 21, 532–546, April 17, 2012 ª2012 Elsevier Inc. 541
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Figure 6. MAP1LC3B Is a Direct Target of MiR-204
(A) (a)Sequence of the wild-type (WT) miR-204 site in the 30UTR of LC3B and mutation (mut) of the core binding site. (b) The 30UTR of LC3B with the wild-type but
not mutant miR-204 site confers regulation by miR-204 to the luciferase reporter construct.
(B) Effects of an anti-miR-204 lentiviral Zip or siRNAs on LC3B protein expression in 786-O VHL(+) RCC cells shown by western blot and quantification of three
independent experiments.
(C) Regression analysis showing negative correlation between normalized miR-204 level and normalized LC3B protein level in human ccRCC tumors with the
wild-type VHL, performed as described in Figure 2D.
(D) Representative western blot showing tumors with high and low levels of LC3B. Normalized values ofmiR-204 levels for each tumor are shown in a graph below
the blot. Expression of LC3B in 786-O cells is shown as reference.
(E) Western blot showing accumulation of LC3B-II in 786-O VHL(+) cells treated with anti-miR-204 in the absence or presence of 100 mM chloroquine.
(F) 786-O VHL() cells transfected with RFP-LC3B or RFP were sorted, plated, and maintained for 48 hr in medium containing 0.1% serum. Cells were then
treatedwith 25 nM short pre-miR-204 or scramble control construct and, 48 hr later, stained by DAPI. Fraction of live cells was determined among the stained and
unstained cells in both conditions.
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Figure 7. VHL-Induced Expression of LC3C Protects RCC Cells from Inhibition of LC3B-Dependent Autophagy
(A) Western blot showing time course of LC3C-II induction in VHL(+) and VHL() 786-O and A498 cells in response to serum starvation.
(B) Quantitative RT-PCR for LC3C and LC3B mRNAs (48 hr of starvation) in VHL(+) as compared with VHL() cells.
(C) Quantitative RT-PCR for LC3C mRNA in VHL() cells where HIF-2a was knocked down by using siRNA.
(D) Quantitative RT-PCR for LC3C mRNA in VHL(+) cells where HIF was stimulated with DMOG (1 mM) for 16 hr.
(E) Effect of single LC3C or LC3B knockdown or of double LC3C/LC3B knockdown on the viability of indicated cells, as compared with scramble-treated cells.
The timeline followed was the same as that shown in Figure 3A.
See also Figure S7.
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Regulation of Autophagy by VHLperformed on a JEOL 1230 TEM at an accelerating voltage of 80 kV. Images
were acquired with an AMT Advantage Plus 2K3 2K digital camera connected
to the TEM.
LC3B Rescue Experiments
Cells were plated at 85,000 cells per 60mmplate in regular medium containing
10% fetal bovine serum (FBS). Transfections with LC3B-RFP or RFP construct
were performed 24 hr later using Lipofectamine LTX and PLUS reagent
(Invitrogen) according to the manufacturer’s protocol. Expression of RFP
was clearly visible by 24 hr to 30 hr after transfection. Cells were then collected
and sorted using a BD FACSAria. Sorted cells were plated at a density of
5,000 per well in 12-well plates in normal medium with 10% FBS with added(G) Quantification of endogenous ATG16L puncta per cell in 786-O VHL() cells tr
red cells, a plus sign indicates cells expressing RFP fluorescence from either con
Numbers of cells (n) in which puncta were counted are shown below the graph.
(H) Effect of LC3B knockdown on cell death induced by miR-204. 786-O or A498
construct were additionally transfected with miR-204 or scramble control. Two in
and Pool 2). N, nontreated cells; L, cells transfected with Lipofectamine only; Scr, c
50 nM of pre-miR-204.
See also Figure S6.antibiotics and antimycotics. Twenty-four hours after plating, the medium
was replaced with medium containing 0.1% serum. After 48 hr of starvation,
cells were transfected with 25 nM of pre-miR-204 precursor or a negative
control construct (Ambion) by using Lipofectamine 2000. On the last day, cells
were collected, stained with DAPI to distinguish live cells, and the percentage
of RFP+ cells was determined, among both viable and dead cell populations,
by flow cytometry.
Statistical Analysis
For descriptive statistics, data are expressed as mean ± SEM unless indicated
otherwise. Analysis of differential expression was performed using one-way
analysis of variance, followed by Tukey-Kramer multiple comparison tests.ansfected with LC3B-RFP or RFP alone and treated with miR-204 as in (F). For
struct, and a minus sign indicates cells that did not express RFP fluorescence.
VHL() cells stably transfected with two different LC3B shRNAs or scramble
dependent pools of 786-O cells expressing LC3B sh I RNA were used (Pool 1
ells transfected with scramble pre-miR-204 control; 204, cells transfectedwith
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Figure 8. LC3B-Dependent Macroautophagy Is Necessary for RCC Tumor Growth
(A) Growth of tumors formed by 786-O VHL() cells in subcutaneous xenografts injected with packaged lentiviruses containing two different shRNAs against
LC3B, or one against ATG5, as compared with the growth of control tumors injected with scramble sequence-containing virus. The number of mice in each
experiment is shown in parentheses above the graph.
(B) Growth of tumors formed by pools of 786-O VHL() cells stably transfected with two different shRNAs against ATG5 or one against LC3B, and injected under
the kidney capsule in nude mice. Western blots show levels of protein knockdown in stable pools of cells under conditions of 10% serum starvation. Cells were
plated and grown for 48 hr in medium containing 10% serum before injection.
(C) Growth of tumors formed by pools of A498 VHL() cells stably transfected with two different shRNAs against LC3B and one against ATG5 and injected under
the kidney capsule in nude mice. Western blots show levels of protein knockdown in stable pools of cells. Cells were treated as in (B). Photographs of repre-
sentative tumors are shown with dashed lines drawn to help visualize the tumors.
(D) There is a significant decrease in the level of miR-204 (p < 0.001) and a significant increase in the level of LC3B (p < 0.05) correlating with tumor grade in human
ccRCC tumors. Because of the small number of tumors classified as Grades 1 and 4, the statistical comparison wasmade between combined subpopulations of
G1+G2 versus G3+G4 tumors. The number of tumors of each grade is provided in parentheses at the bottom. Statistics were calculated as in Figure 1B. Means ±
SD are shown.
(E) Formation of tumors in orthotopic xenografts by VHL(+) 786-O and A498 with stable knockdowns of LC3C using two different LC3C shRNAs in each cell line.
The table lists numbers of mice analyzed and photographs of representative tumors are shown. Dashed lines help visualize tumorigenic infiltrate of A498 cells. All
scale bars, 1 cm.
(F) Schematic representation of the role of VHL in the regulation of autophagy in RCC tumor growth.
See also Figure S8.
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Regulation of Autophagy by VHLDifferences where p < 0.05 were considered to be statistically significant. In
quantitative immunoblotting experiments, we used log2-transformed normal-
ized values to facilitate robust and outlier-insensitive analyses. Standard
box-and-whisker plots were used to compare distributions of the normalized
abundance measure for individual proteins. Correlations between variables
were assessed by means of regression analysis and by Pearson and
Spearman rank correlation coefficients.SUPPLEMENTAL INFORMATION
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